sorafenib has been researched along with Pneumatosis Cystoides Intestinalis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, YH; Siao, FY; Yen, HH | 1 |
| Billemont, B; Blanchet, B; Chaussade, S; Coriat, R; Goldwasser, F; Massault, PP; Mir, O; Ropert, S; Vignaux, O | 1 |
| Kashima, T; Ohno, Y; Tachibana, M | 1 |
3 other study(ies) available for sorafenib and Pneumatosis Cystoides Intestinalis
| Article | Year |
|---|---|
Abdominal Distension in a Patient With Hepatocellular Carcinoma. Benign Pneumatosis Intestinalis and Pneumoperitoneum Associated With Sorafenib Therapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Jejunum; Liver Neoplasms; Male; Niacinamide; Peritoneal Cavity; Phenylurea Compounds; Pneumatosis Cystoides Intestinalis; Pneumoperitoneum; Sorafenib; Tomography, X-Ray Computed | 2015 |
Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.
Topics: Adult; Benzenesulfonates; Disease Progression; Fatal Outcome; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pneumatosis Cystoides Intestinalis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Diagnosis, Differential; Female; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pneumatosis Cystoides Intestinalis; Portal Vein; Sorafenib | 2012 |